Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02648178 · ClinicalTrials.gov registry record · NA

Evaluation of Appeal and Impact of E-Cigarettes Among Chronic Smokers With Smoking-Related Cancers

A NA study of Lung Cancer and Bladder Cancer, sponsored by Dartmouth-Hitchcock Medical Center.

Completed
Registry status
NA
Development phase
19
Enrollment target
1
Study location

NCT02648178 is a NA study of Lung Cancer and Bladder Cancer that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 19 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02648178, a NA study of Lung Cancer and Bladder Cancer, has completed, sponsored by Dartmouth-Hitchcock Medical Center.

COMPLETED
Registry status
NA
Development phase
19 participants
Enrollment target
1
Study location

Study Summary

This study will test feasibility, in smokers with lung, head \& neck, and bladder cancers, that examines the effect of e-cigarette substitution, on measures of smoking-related toxicity and medical outcomes. The aim of the study is to determine the appeal of e-cigarettes compared to regular combustible cigarettes.

Interventions

  • DEVICE HALO

Study Locations (1)

New Hampshire

  • Dartmouth Hitchcock Medical Center - Lebanon

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2016-06
Est. Completion 2018-05
Phase NA

Sponsor

Dartmouth-Hitchcock Medical Center

427 total trials

What the Registry Record Tells You About NCT02648178

The ClinicalTrials.gov registry entry for NCT02648178 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which HALO is the first listed.

NCT02648178 reports 1 study location spanning 1 distinct geographic area - top geographies include New Hampshire.

Frequently Asked Questions

What is clinical trial NCT02648178 about?

NCT02648178 is a clinical study titled "Evaluation of Appeal and Impact of E-Cigarettes Among Chronic Smokers With Smoking-Related Cancers". This study will test feasibility, in smokers with lung, head \& neck, and bladder cancers, that examines the effect of e-cigarette substitution, on measures of smoking-related toxicity and medical outcomes. The aim of the study is to determine the appeal of e-cigarettes compared to regular combustib...

What is the current status of trial NCT02648178?

This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2016-06. Estimated completion is 2018-05.

What conditions does trial NCT02648178 study?

This clinical trial studies the following conditions: Lung Cancer, Bladder Cancer, Cancer of Head and Neck, Nicotine Dependence, Other Tobacco Product.

What interventions are being tested in trial NCT02648178?

The interventions under investigation include: HALO (DEVICE).

Who is sponsoring clinical trial NCT02648178?

This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02648178 being conducted?

This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.